Data gathered: April 15
AI Stock Analysis - Vertex Pharmaceuticals (VRTX)
Analysis generated December 29, 2024. Powered by Chat GPT.
Vertex Pharmaceuticals is a global biotechnology company focused on the discovery, development, and commercialization of innovative new medicines for serious diseases. The company is primarily involved in developing therapies for cystic fibrosis and has a robust pipeline of potential treatments for other serious illnesses. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has established a strong presence in the biotech sector through its groundbreaking research and significant contributions to medical science.
Stock Alerts - Vertex Pharmaceuticals (VRTX)
 |
Vertex Pharmaceuticals | March 18 Insider Alert: ALTSHULER DAVID is selling shares |
|
Vertex Pharmaceuticals | March 18 Employee Rating is down by 2.4% over the last month. |
|
Vertex Pharmaceuticals | March 13 Insider Alert: Tatsis Ourania is continuing selling shares |
|
Vertex Pharmaceuticals | March 11 Jefferson Shreve (member of U.S. congress) is buying shares |
Alternative Data for Vertex Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 226 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 263,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 283 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 11,606 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 21 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,199 | Sign up | Sign up | Sign up |
| Twitter Followers | 71,018 | Sign up | Sign up | Sign up |
| Twitter Mentions | 35 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,570 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 68 | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 5,849 | Sign up | Sign up | Sign up |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
| Price | $495.83 |
| Target Price | Sign up |
| Volume | 1,360,000 |
| Market Cap | $124B |
| Year Range | $396.64 - $516.74 |
| Dividend Yield | 0% |
| PE Ratio | 32.11 |
| Analyst Rating | 62% buy |
| Earnings Date | May 5 '25 |
| Industry | Biotechnology |
In the news
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading dayApril 14 - MarketWatch |
|
 |
Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) PT at $509.17April 13 - ETF Daily News |
|
Zacks Research Brokers Increase Earnings Estimates for VRTXApril 11 - ETF Daily News |
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?April 11 - Yahoo Entertainment |
|
 |
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should KnowApril 10 - Yahoo |
 |
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) FranchiseApril 10 - Yahoo Entertainment |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 2.91B | 423M | 2.49B | 913M | 1.19B | 3.980 |
| Q3 '24 | 2.77B | 393M | 2.38B | 1.05B | 1.28B | 4.380 |
| Q2 '24 | 2.63B | 372M | 2.26B | -3.59B | -3.33B | -12.830 |
| Q1 '24 | 2.69B | 343M | 2.34B | 1.1B | 1.34B | 4.760 |
| Q4 '23 | 2.52B | 368M | 2.15B | 969M | 1.22B | 4.200 |
Insider Transactions View All
| ALTSHULER DAVID filed to sell 23,281 shares at $510. March 17 '25 |
| ALTSHULER DAVID filed to sell 26,512 shares at $500. March 12 '25 |
| Tatsis Ourania filed to sell 51,239 shares at $500. March 12 '25 |
| WAGNER CHARLES F JR filed to sell 51,671 shares at $500. March 12 '25 |
| Tatsis Ourania filed to sell 54,481 shares at $485.5. March 6 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Jefferson Shreve |
Mar 10, 25 | Buy | $15K - $50K |
| Ro Khanna |
Dec 6, 24 | Buy | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
Read more about Vertex Pharmaceuticals (VRTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Vertex Pharmaceuticals?
The Market Cap of Vertex Pharmaceuticals is $124B.
What is Vertex Pharmaceuticals' PE Ratio?
As of today, Vertex Pharmaceuticals' PE (Price to Earnings) ratio is 32.11.
When does Vertex Pharmaceuticals report earnings?
Vertex Pharmaceuticals will report its next earnings on May 5 '25.
What is the current stock price of Vertex Pharmaceuticals?
Currently, the price of one share of Vertex Pharmaceuticals stock is $495.83.
How can I analyze the VRTX stock price chart for investment decisions?
The VRTX stock price chart above provides a comprehensive visual representation of Vertex Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vertex Pharmaceuticals shares. Our platform offers an up-to-date VRTX stock price chart, along with technical data analysis and alternative data insights.
Does VRTX offer dividends to its shareholders?
As of our latest update, Vertex Pharmaceuticals (VRTX) does not offer dividends to its shareholders. Investors interested in Vertex Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vertex Pharmaceuticals?
Some of the similar stocks of Vertex Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.